Amundi Buys 175,108 Shares of Veeva Systems Inc. $VEEV

Amundi boosted its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 35.8% during the second quarter, Holdings Channel.com reports. The firm owned 664,075 shares of the technology company’s stock after purchasing an additional 175,108 shares during the quarter. Amundi’s holdings in Veeva Systems were worth $187,674,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VEEV. Sigma Planning Corp lifted its position in shares of Veeva Systems by 1.2% during the second quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock valued at $958,000 after buying an additional 39 shares during the last quarter. Keybank National Association OH raised its stake in shares of Veeva Systems by 1.4% during the 2nd quarter. Keybank National Association OH now owns 3,088 shares of the technology company’s stock worth $889,000 after acquiring an additional 42 shares in the last quarter. Facet Wealth Inc. raised its stake in shares of Veeva Systems by 3.3% during the 2nd quarter. Facet Wealth Inc. now owns 1,342 shares of the technology company’s stock worth $381,000 after acquiring an additional 43 shares in the last quarter. TFB Advisors LLC lifted its position in Veeva Systems by 1.2% during the first quarter. TFB Advisors LLC now owns 3,586 shares of the technology company’s stock valued at $831,000 after acquiring an additional 44 shares during the last quarter. Finally, Triangle Securities Wealth Management boosted its stake in Veeva Systems by 0.8% in the second quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock valued at $1,665,000 after acquiring an additional 45 shares in the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on VEEV. Wells Fargo & Company reduced their price target on Veeva Systems from $341.00 to $333.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 25th. Evercore ISI boosted their target price on Veeva Systems from $285.00 to $295.00 and gave the stock an “in-line” rating in a research note on Thursday, August 28th. Wall Street Zen lowered Veeva Systems from a “buy” rating to a “hold” rating in a research report on Saturday. Jefferies Financial Group reiterated a “buy” rating and issued a $330.00 price target on shares of Veeva Systems in a research note on Monday, November 24th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $340.00 price target (up previously from $310.00) on shares of Veeva Systems in a report on Thursday, August 28th. Nineteen research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $307.42.

Insider Buying and Selling

In other Veeva Systems news, insider Thomas D. Schwenger sold 3,350 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the sale, the insider directly owned 23,773 shares of the company’s stock, valued at approximately $7,132,850.92. This trade represents a 12.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of Veeva Systems stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total value of $1,839,720.00. Following the transaction, the insider owned 25,325 shares of the company’s stock, valued at $7,765,151.50. The trade was a 19.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 24,665 shares of company stock valued at $7,438,000 over the last 90 days. Insiders own 10.30% of the company’s stock.

Veeva Systems Stock Down 0.1%

Shares of NYSE:VEEV opened at $242.06 on Friday. Veeva Systems Inc. has a 52-week low of $201.54 and a 52-week high of $310.50. The stock has a market cap of $39.79 billion, a price-to-earnings ratio of 47.09, a PEG ratio of 1.80 and a beta of 1.05. The business has a 50-day moving average price of $280.03 and a 200-day moving average price of $278.86.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Thursday, November 20th. The technology company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.09. Veeva Systems had a net margin of 27.93% and a return on equity of 13.68%. The company had revenue of $0.81 million for the quarter, compared to the consensus estimate of $792.37 million. During the same quarter in the prior year, the company earned $1.75 EPS. Veeva Systems’s quarterly revenue was up 16.0% on a year-over-year basis. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. As a group, equities analysts anticipate that Veeva Systems Inc. will post 4.35 EPS for the current fiscal year.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.